Progress of monoclonal antibodies in the treatment of autoimmune diseases

Tong Xu

doi:10.54097/f4hfac33

Authors

Tong Xu

DOI:

https://doi.org/10.54097/f4hfac33

Keywords:

Autoimmune disease; Immune system；Monoclonal antibody.

Abstract

Autoimmune diseases are a hot issue in today's society, and some researchers have found that monoclonal antibodies can be used to treat autoimmune diseases. Autoimmune diseases are a class of diseases caused by abnormal attacks of the immune system on its own tissues, and monoclonal antibodies, as a kind of targeted therapy, have high specificity and selectivity. This article analyses the etiology and pathology of autoimmune diseases, as well as the therapeutic principle and preparation of monoclonal antibodies. Through the comprehensive analysis of the research, it is found that monoclonal antibodies can effectively target the key molecules or cells of autoimmune diseases, reduce inflammatory response and improve the condition. However, challenges faced by monoclonal antibodies, such as drug resistance and adverse reactions, were also pointed out. Further research on the mechanism of action of monoclonal antibodies is needed in the future to optimize the treatment regimen in order to improve its therapeutic efficacy and safety.

Downloads

Download data is not yet available.

References

Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119-125.

Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-395.

Silvestri I, Taniuchi H. A study of fine specificity of monoclonal antibodies to yeast iso-1-cytochrome c. J Biol Chem. 1988;263(35):18702-18715.

Rosenblum M D, Remedios K A, Abbas A K. Mechanisms of human autoimmunity. The Journal of clinical investigation, 2015, 125(6): 2228-2233.

Angum F, Khan T, Kaler J, et al. The prevalence of autoimmune disorders in women: a narrative review. Cureus, 2020, 12(5).

Shi G, Zhang J, Zhang Z J, et al. Systemic autoimmune diseases. Journal of Immunology Research, 2013, 2013.

Medzhitov R. Origin and physiological roles of inflammation. Nature, 2008, 454(7203): 428-435.

Delves P J, Roitt I M. The immune system. New England journal of medicine, 2000, 343(1): 37-49.

Dominguez-Villar M, Hafler D A. Regulatory T cells in autoimmune disease. Nature immunology, 2018, 19(7): 665-673.

Kelchtermans H, Billiau A, Matthys P. How interferon-γ keeps autoimmune diseases in check. Trends in immunology, 2008, 29(10): 479-486.

Brembilla N C, Senra L, Boehncke W H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Frontiers in immunology, 2018, 9: 387937.

Saraiva M, O'garra A. The regulation of IL-10 production by immune cells. Nature reviews immunology, 2010, 10(3): 170-181.

Nelson P N, Reynolds G M, Waldron E E, et al. Demystified…: monoclonal antibodies. Molecular pathology, 2000, 53(3): 111.

Singh S, Tank N K, Dwiwedi P, et al. Monoclonal antibodies: a review. Current clinical pharmacology, 2018, 13(2): 85-99.

Beare A, Stockinger H, Zola H, Nicholson I. Monoclonal antibodies to human cell surface antigens. Curr Protoc Immunol. 2008;Appendix 4(1):A.4A.1-A.4A.73.

Goding J W. Antibody production by hybridomas. Journal of immunological methods, 1980, 39(4): 285-308.

Braun J, Sieper J. Ankylosing spondylitis. The Lancet, 2007, 369(9570): 1379-1390.

Bartelds G M, Wijbrandts C A, Nurmohamed M T, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the rheumatic diseases, 2007, 66(7): 921-926.

Mease P J. Adalimumab in the treatment of arthritis. Therapeutics and clinical risk management, 2007, 3(1): 133-148.

Bang L M, Keating G M. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs, 2004, 18(2): 121-139.

Gils A, Casteele N V, Poppe R, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Therapeutic drug monitoring, 2014, 36(5): 669-673.

Gudjonsson J E, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clinical & Experimental Immunology, 2004, 135(1): 1-8.

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. International journal of molecular sciences, 2019, 20(6): 1475.

Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. New England journal of medicine, 2015, 373(26): 2534-2548.

Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy, 2016, 16(5): 711-722.

Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert opinion on drug safety, 2016, 15(10): 1413-1420.

Mok C C, Lau C S. Pathogenesis of systemic lupus erythematosus. Journal of clinical pathology, 2003, 56(7): 481-490.

Borchers A T, Naguwa S M, Shoenfeld Y, et al. The geoepidemiology of systemic lupus erythematosus. Autoimmunity reviews, 2010, 9(5): A277-A287.

Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs R D. 2008;9(3):197-202.

Pan L, Lu M P, Wang J H, et al. Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics, 2020, 16: 19-30.

Chiche L, Jourde N, Thomas G, et al. New treatment options for lupus–a focus on belimumab. Therapeutics and Clinical Risk Management, 2012: 33-43.